Interestingly, although there was a spectrum of dose-dependent antitumour activity ranging from dramatic tumour regression to de novo resistance when gefitinib was tested in multiple human tumour xenograft studies, the level of EGFR expression did not predict tumour response (Wakeling et al, 2002). The gene discussed is EGFR; the disease is neoplasm.